The Value of Open Access and a Patient Centric Approach to Oral Oncolytic Utilization in the Treatment of Chronic Myelogenous Leukemia: A U.S. Perspective

Expert Review of Pharmacoeconomics and Outcomes Research - United Kingdom
doi 10.1080/14737167.2017.1305892
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Concomitant Renal Cell Carcinoma and Chronic Myelogenous Leukemia: Utilization of a Targeted Approach

Current Oncology
Oncology
2009English

Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Pharmacotherapy for Chronic Myelogenous Leukemia: A Case-Based Approach

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2011English

A Case of Recurrent Cerebral Infarction During Treatment With Oral Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clinical Neurology
Neurology
2019English

Bosutinib in the Management of Chronic Myelogenous Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2013English

Chronic Myelogenous Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Dasatinib Induces Severe Hemorrhagic Colitis in a Patient With Accelerated Phase of Chronic Myelogenous Leukemia

Korean Journal of Internal Medicine
Internal Medicine
2018English

Disease Management and Treatment of Chronic Myeloid Leukemia (CML): Experience From the Patient (Pt) Perspective.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Erythroid Variant of Chronic Myelogenous Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy